Pharmacokinetics and pharmacodynamics of the acetylcholinesterase inhibitor metrifonate in patients with renal impairment

Therapeutic Drug Monitoring

Volumn 21, Issue 3, 1999, Pages 310-316

  Dingemanse, Jasper ^a,c   Halabi, Atef ^a   Kleinbloesem, Cornelis H ^a   Heinig, Roland ^b   Blume, Hildegard ^b  

^a Clin Pharma Research AG   (Switzerland)

^b BAYER AG   (Germany)

^c Clin Pharma Research Ltd   (Switzerland)

Author keywords

Metrifonate; Pharmacodynamics; Pharmacokinetics; Renal function

Indexed keywords

ACETYLCHOLINESTERASE; CHOLINESTERASE; CHOLINESTERASE INHIBITOR; DICHLOROACETIC ACID; DICHLORVOS; METRIFONATE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DRUG EXCRETION; DRUG MECHANISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG URINE LEVEL; ENZYME INHIBITION; FEMALE; HUMAN; KIDNEY FAILURE; KIDNEY FUNCTION; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

AGED; CHOLINESTERASE INHIBITORS; FEMALE; HUMANS; KIDNEY DISEASES; MALE; MIDDLE AGED; TRICHLORFON;

EID: 0033007092     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-199906000-00010     Document Type: Article

References (21)

1. Snellen WM. Therapeutic properties of metrifonate. Acta Pharmacol Toxicol 1981:49(suppl 5): 114-7.
2. Cioli D. Pica-Mattoccia L. Archer S. Antischistosomal drugs: past, present ... and future? Pharmacol Ther 1995;68:35-85.
3. Tariot PN, Schneider L, Porsteinsson AP. Treating Alzheimer's disease. Pharmacologic options now and in the near future. Postgrad Med 1997;101:73-6.
4. Knopman S. Metrifonate for Alzheimer's disease. Is the next cholinesterase inhibitor better? Neurology 1998;50:1203-5.
5. Becker RE, Colliner JA, Markwell SJ, Moriearty PL, Unni LK, Vicari S. Double-blind placebo-controlled study of metrifonate, an acetylcholinesterase inhibitor, for Alzheimer disease. Alzheimer Dis Assoc Disord 1996;10:124-31.
6. Cummings JL, Cyrus PA, Bieber F, Mas J, Orazem J, Gulanski B, and the Metrifonate Study Group. Metrifonate treatment of the cognitive deficits of Alzheimer's disease. Neurology 1998;50: 1214-21.
7. Morris JC, Cyrus PA, Orazem J, Mas J, Bieber F, Ruzicka BB, Gulanski B. Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer's disease. Neurology 1998;50: 1222-30.
8. Unni LK, Womack C, Hannant ME, Becker RE. Pharmacokinetics and pharmacodynamics of metrifonate in humans. Methods Find Exp Clin Pharmacol 1994;16:285-9.
9. Johansson M, Hellström-Lindahl E, Nordberg A. Steady-state pharmacokinetics of tacrine in long-term treatment of Alzheimer patients. Dementia 1996;7:111-7.
10. Barner EL, Gray SL, Donepezil use in Alzheimer disease. Ann Pharmacother 1998;32:70-7.
11. Polinsky RJ. Clinical pharmacology of rivastigmine: a new-generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease. Clin Ther 1998;20:634-47.
12. Good Clinical Practice for Trials on Medicinal Products in the European Community. In: The Rules Governing Medicinal Products in the European Community. Volume III: Guidelines on the quality, safety and efficacy of medicinal products for human use. Luxembourg: Commission of the European Communities: 1990: 57-98.
13. Pettigrew LC, Bieber F, Lettieri J, et al. Pharmacokinetics, pharmacodynamics, and safety of metrifonate in patients with Alzheimer's disease. J Clin Pharmacol 1998;38:236-45.
14. Abdi YA, Villén T. Pharmacokinetics of metrifonate and its rearrangement product dichlorvos in whole blood. Pharmacol Toxicol 1991:68:137-9.
15. Villen T. Abdi YA. Ericsson O. Gustafsson LL, Sjoqvist F. Determination of metrifonate and dichlorvos in whole blood using gas chromatography and gas chromatography-mass spectrometry. J Chromatogr 1990;529:309-17.
16. Pacheco G, Palacios-Esquivel R, Moss DE. Cholinesterase inhibitors proposed for treating dementia in Alzheimer's disease: selectivity toward human brain acetylcholinesterase compared with butyrylcholinesteras. J Pharmacol Exp Ther 1995;274:767-70.
17. Knedel M, Böttger R. Eine kinetische Methode zur Bestimmung der Aktivität der Pseudocholinesterase. Klin Wschr 1967;45: 325-7.
18. Ellmann GL, Courtney KD, Andres V, Featherstone RM. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol 1961;7:88-95.
19. Hofer W. Chemistry of metrifonate and dichlorvos. Acta Pharmacol Toxicol 1981:49(suppl 5):7-14.
20. Nordgren I. Bengtsson E. Holmstedt B. et al. Levels of metrifonate and dichlorvos in plasma and erythrocytes during treatment of schistosomiasis with Bilarcil. Acta Pharmacol Toxicol 1981;49 (suppl 5):79-86.
21. Lamb HM, Faulds D. Metrifonate. Drugs Aging 1997:11:490-6.